Calibration verification/linearity test kits, 9/16
September 2016—LGC Maine Standards released its Validate Tumor Markers and Validate Whole Blood Glucose calibration verification/linearity test kits.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
Streck supply agreements, 9/16
September 2016—Streck and Biodesix, a molecular diagnostics company that develops blood-based tests in oncology, have signed an agreement to make Streck the exclusive supplier of DNA and RNA tubes for Biodesix.
myChoice HRD increases eligible patients, 8/16
August 2016—Myriad Genetics announced that its myChoice HRD test successfully identified an increased number of patients with ovarian cancer who may benefit from treatment with niraparib, an investigational oral PARP inhibitor being developed by Tesaro. The announcement follows results of the NOVA study, which evaluated the safety and efficacy of niraparib as a maintenance therapy in more than 500 patients with recurrent ovarian cancer.
Blood collection device, 8/16
August 2016—Streck’s Cell-Free DNA BCT, for the collection and preservation of whole blood samples, is available as a 2.0 mL draw tube. The formaldehyde-free preservative reagent contained in Cell-Free DNA BCT inhibits nuclease-mediated degradation of cf-DNA and stabilizes nucleated blood cells, which prevents the release of cellular genomic DNA. Samples are stable for up to 14 days at temperatures between 6°–37°C, allowing convenient sample collection, transport, and storage.
Liquid biopsy PD-L1 test, 8/16
August 2016—Biocept launched its CLIA-validated PD-L1 protein expression test, which uses Biocept’s proprietary, patented Target Selector platform with circulating tumor cells from a patient’s blood sample and can be used to detect and monitor PD-L1 protein expression throughout the course of a patient’s cancer therapy.
FISH slide hybridizer, 8/16
August 2016—Boekel Scientific introduced its RapidFISH slide hybridizer designed to simplify fluorescence in situ hybridization procedures for formalin-fixed, paraffin-embedded tissue samples, cell suspensions, and other tissue preparation procedures. The RapidFISH has a self-clamping slide tray design that maintains the required humidity and has an easy-to-use control system for temperature, time, and controlled temperature steps.
Ergonomically designed microscope, 8/16
August 2016—The Olympus BX46 microscope’s specially designed ergonomic features aim to provide enhanced operator comfort during long hours of use.
Gross room lab tray, 8/16
August 2016—Safety-Spec, a pathologist-owned company, has announced that the Gross Room Lab Tray is available for order on its website, Safety-Spec.com. Designed by a pathologist and laboratory scientist, the tray provides improved specimen organization in the gross room queue, resulting in increased efficiency and patient safety by reducing the potential for misidentification of specimens from a patient (intra-accession mislabeling) as well as misidentification between patients (inter-accession mislabeling).
Studies cite utility of molecular cancer classification test, 8/16
August 2016—A study published in Oncotarget (Brachtel EF, et al. Epub ahead of print March 28, 2016) demonstrates the high accuracy and success rate of Biotheranostics’ CancerType ID molecular cancer classifier in the diagnosis of cancer for specimens with limited tissue. Results from the study support additional clinical utility for CancerType ID in small biopsy and cytology cases.
D-dimer test kit, 8/16
August 2016—LGC Maine Standards announced its Validate D-Dimer calibration verification/linearity test kit has received 510(k) clearance for use on Instrumentation Laboratory’s ACL TOP hemostasis test systems. The kit evaluates D-dimer in a human-plasma base matrix, is prepared using the CLSI recommended “equal delta” method for linearity testing, and is liquid, ready to use.